Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products:: Biochemical mechanisms

被引:248
作者
Miyata, T [1 ]
De Strihou, CV
Ueda, Y
Ichimori, K
Inagi, R
Onogi, H
Ishikawa, N
Nangaku, M
Kurokawa, K
机构
[1] Tokai Univ, Sch Med, Inst Med Sci, Kanagawa 2591193, Japan
[2] Tokai Univ, Sch Med, Dept Med, Kanagawa 2591193, Japan
[3] Catholic Univ Louvain, Serv Nephrol, Brussels, Belgium
[4] Univ Tokyo, Sch Med, Div Nephrol & Endocrinol, Tokyo 113, Japan
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷 / 10期
关键词
D O I
10.1097/01.ASN.0000032418.67267.F2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The implication of advanced glycation end products (AGE) in the pathogenesis of atherosclerosis and of diabetic and uremic complications has stimulated a search for AGE inhibitors. This study evaluates the AGE inhibitory potential of several well-tolerated hypotensive drugs. Olmesartan, an angiotensin II type 1 receptor (AIIR) antagonist, as well as temocaprilat, an angiotensin-converting enzyme (ACE) inhibitor, unlike nifedipine, a calcium blocker, inhibit in vitro the formation of two AGE, pentosidine and N-epsilon-carboxymethyllysine (CML), during incubation of nonuremic diabetic, nondiabetic uremic, or diabetic uremic plasma or of BSA fortified with arabinose. This effect is shared by all tested AIIR antagonists and ACE inhibitors. On an equimolar basis, they are more efficient than aminoguanidine or pyridoxamine. Unlike the latter two compounds, they do not trap reactive carbonyl precursors for AGE, but impact on the production of reactive carbonyl precursors for AGE by chelating transition metals and inhibiting various oxidative steps, including carbon-centered and hydroxyl radicals, at both the pre- and post-Amadori steps. Their effect is paralleled by a lowered production of reactive carbonyl precursors. Finally, they do not bind pyridoxal, unlike aminoguanidine. Altogether, this study demonstrates for the first time that widely used hypotensive agents, AIIR antagonists and ACE inhibitors, significantly attenuate AGE production. This study provides a new framework for the assessment of families of AGE-lowering compounds according to their mechanisms of action.
引用
收藏
页码:2478 / 2487
页数:10
相关论文
共 54 条
[1]  
AHMED MU, 1986, J BIOL CHEM, V261, P4889
[2]  
Akhand AA, 1999, J CELL BIOCHEM, V72, P1, DOI 10.1002/(SICI)1097-4644(19990101)72:1<1::AID-JCB1>3.0.CO
[3]  
2-Y
[4]   The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins:: a mechanism for producing advances glycation end products at sites of inflammation [J].
Anderson, MM ;
Requena, JR ;
Crowley, JR ;
Thorpe, SR ;
Heinecke, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (01) :103-113
[5]   Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein - A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation [J].
Anderson, MM ;
Hazen, SL ;
Hsu, FF ;
Heinecke, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (03) :424-432
[6]  
[Anonymous], 1996, ENDOCRINOL METAB
[7]   Nitric oxide inhibits the formation of advanced glycation end products [J].
Asahi, K ;
Ichimori, K ;
Nakazawa, H ;
Izuhara, Y ;
Inagi, R ;
Watanabe, T ;
Miyata, T ;
Kurokawa, K .
KIDNEY INTERNATIONAL, 2000, 58 (04) :1780-1787
[8]   A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF ENALAPRIL IN PATIENTS WITH CLINICAL DIABETIC NEPHROPATHY [J].
BAUER, JH ;
REAMS, GP ;
HEWETT, J ;
KLACHKO, D ;
MESSINA, C ;
KNAUS, V .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (05) :443-457
[9]   ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES [J].
BAYNES, JW .
DIABETES, 1991, 40 (04) :405-412
[10]   INCREASED COLLAGEN-LINKED PENTOSIDINE LEVELS AND ADVANCED GLYCOSYLATION END-PRODUCTS IN EARLY DIABETIC NEPHROPATHY [J].
BEISSWENGER, PJ ;
MOORE, LL ;
BRINCKJOHNSEN, T ;
CURPHEY, TJ .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) :212-217